In this regard, the findings of Zhang and colleagues propose to target NF-κB through the axis HIPK2–HDAC3–NF-κB to ameliorate not only colitis-associated colorectal cancer and sepsis but also inflammation-related cancers [46] (Table 1). Here, HIPK2 is linked to colitis.